The online version of this article (doi:10.1186/1475-2840-11-14) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
BW, LGK, MO, PMS: Conception, data acquisition, analysis, drafting and revising manuscript. DLH, LMB: Data acqusition, analysis, drafting and revising manuscript. All authors read and approved the final manuscript.
The prognostic benefits of beta-blockers (BB) in patients with systolic heart failure (SHF) are known but despite this, in patients with diabetes they are underutilized. The aim of this study was to assess the effect of beta-blockers (BB) on glycaemic control in patients with Type 2 Diabetes (T2DM) and systolic heart failure (SHF) stratified to beta-1 selective (Bisoprolol) vs. nonselective BB (Carvedilol).
This observational, cohort study was conducted in patients with T2DM and SHF attending an Australian tertiary teaching hospital's heart failure services. The primary endpoint was glycaemic control measured by glycosylated haemoglobin (HbA1c) at initiation and top dose of BB. Secondary endpoints included microalbuminuria, changes in lipid profile and estimated glomerular filtration rate (eGFR).
125 patients were assessed. Both groups were well matched for gender, NYHA class and use of guideline validated heart failure and diabetic medications. The mean treatment duration was 1.9 ± 1.1 years with carvedilol and 1.4 ± 1.0 years with bisoprolol (p = ns). The carvedilol group achieved a reduction in HbA1c (7.8 ± 0.21% to 7.3 ± 0.17%, p = 0.02) whereas the bisoprolol group showed no change in HbA1c (7.0 ± 0.20% to 6.9 ± 0.23%, p = 0.92). There was no significant difference in the change in HbA1c from baseline to peak BB dose in the carvedilol group compared to the bisoprolol group. There was a similar deterioration in eGFR, but no significant changes in lipid profile or microalbuminuria in both groups (p = ns).
BB use did not worsen glycaemic control, lipid profile or albuminuria status in subjects with SHF and T2DM. Carvedilol significantly improved glycemic control in subjects with SHF and T2DM and this improvement was non significantly better than that obtained with bisoprolol. BB's should not be withheld from patients with T2DM and SHF.
Authors’ original file for figure 112933_2011_439_MOESM1_ESM.tiff
Hunt SA: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005, 46: e1-82. 10.1016/j.jacc.2005.08.022. CrossRefPubMed
Yilmaz MB, Refiker M, Guray Y, Guray U, Altay H, Demirkan B, Caldir V, Korkmaz S: Prescription patterns in patients with systolic heart failure at hospital discharge: why beta blockers are underprescribed or prescribed at low dose in real life?. Int J Clin Pract. 2007, 61: 225-230. 10.1111/j.1742-1241.2006.01157.x. CrossRefPubMed
ASHP therapeutic position statement on the use of beta-blockers in survivors of acute myocardial infarction. Am J Health Syst Pharm. 2002, 59: 2226-2232.
Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJ, Anker SD: Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005, 46: 1019-1026. 10.1016/j.jacc.2005.02.093. CrossRefPubMed
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000, 321: 405-412. 10.1136/bmj.321.7258.405. PubMedCentralCrossRefPubMed
Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Jama. 2004, 292: 2227-2236. 10.1001/jama.292.18.2227. CrossRefPubMed
Srivastava PM, Thomas MC, Calafiore P, MacIsaac RJ, Jerums G, Burrell LM: Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. Clin Sci (Lond). 2006, 110: 109-116. 10.1042/CS20050184. CrossRef
Fonseca V, Bakris GL, Bell DS, McGill JB, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT, Waterhouse B: Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med. 2007, 24: 759-763. 10.1111/j.1464-5491.2007.02151.x. CrossRefPubMed
Kveiborg B, Hermann TS, Major-Pedersen A, Christiansen B, Rask-Madsen C, Raunso J, Kober L, Torp-Pedersen C, Dominguez H: Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study. Cardiovasc Diabetol. 2010, 9: 21-10.1186/1475-2840-9-21. PubMedCentralCrossRefPubMed
Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996, 14: 489-494. PubMed
Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V: Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications. 2008, 22: 303-308. 10.1016/j.jdiacomp.2007.05.003. PubMedCentralCrossRefPubMed
Falskov B, Hermann TS, Raunso J, Christiansen B, Rask-Madsen C, Major-Pedersen A, Kober L, Torp-Pedersen C, Dominguez H: Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure-a randomized study. Cardiovasc Diabetol. 2011, 10: 91-10.1186/1475-2840-10-91. PubMedCentralCrossRefPubMed
Pollare T, Lithell H, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Bmj. 1989, 298: 1152-1157. 10.1136/bmj.298.6681.1152. PubMedCentralCrossRefPubMed
Haas SJ, Vos T, Gilbert RE, Krum H: Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J. 2003, 146: 848-853. 10.1016/S0002-8703(03)00403-4. CrossRefPubMed
- Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control
Leighton G Kearney
David L Hare
Louise M Burrell
Piyush M Srivastava
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II